Interaction between Ketorolac and Meloxicam
Major
Synergy
| ID | DDInter1010 and DDInter1143 |
| Interaction |
The use of ketorolac in combination with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious adverse effects such as renal failure and gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines.
abdominal distension
abdominal pain
abscess
anaemia
angioedema
Anxiety
arthritis
asthenia
asthma
AFIB
More
|
| Management | Concurrent use of ketorolac with other NSAIDs or aspirin is considered contraindicated. |
| References | |
| Alternative for Ketorolac |
M01A
Chondroitin sulfate
Glucosamine
Suprofen (ophthalmic)
Esomeprazole
Diclofenac (ophthalmic)
Flurbiprofen (ophthalmic)
S01F
More
|
| Alternative for Meloxicam |
M01A
|
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.